carbon monoxide has been researched along with Airflow Obstruction, Chronic in 139 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assumed that the level of expired-air carbon monoxide may not useful in assessing the severity of inflammation in COPD (Tab." | 7.74 | Does the expired-air carbon monoxide level reflect the severity of inflammation in COPD? ( Hanta, I; Kocabas, A; Olgunus, O; Satar, S; Seydaoglu, G, 2007) |
| "Three hundred thirty-one consecutive outpatients (161 with asthma and 170 with COPD) were examined cross-sectionally by self-reported smoking status, breath CO monitoring, and serum cotinine concentration." | 7.72 | Optimal cutoff level of breath carbon monoxide for assessing smoking status in patients with asthma and COPD. ( Hajiro, T; Koyama, H; Mishima, M; Nishimura, K; Oga, T; Sato, S; Tsukino, M, 2003) |
| "Alpha(1)-AT-deficient and COPD patients had lower exhaled CO(2) than controls, although only alpha(1)-AT-deficient patients had higher exhaled O(2) than healthy controls." | 5.31 | Low levels of nitric oxide and carbon monoxide in alpha 1-antitrypsin deficiency. ( Dweik, RA; Erzurum, SC; Laskowski, D; Lupica, JA; Machado, RF; Stoller, JK; Zheng, S, 2002) |
| "We studied 21 COPD patients in stable clinical conditions to evaluate whether changes in lung function induced by cumulative doses of salbutamol alter diffusing capacity for carbon monoxide (DL(CO)), and whether this relates to the extent of emphysema as assessed by high resolution computed tomography (HRCT) quantitative analysis." | 5.12 | Effect of bronchodilatation on single breath pulmonary uptake of carbon monoxide in chronic obstructive pulmonary disease. ( Baldi, S; Brusasco, V; Bruschi, C; Dore, R; Fracchia, C; Maestri, R; Pellegrino, R, 2006) |
| " Subjects were included if they had received furosemide, 40 mg/d, for the treatment of peripheral edema for at least a month and if they had a mean nocturnal arterial oxygen saturation (SaO(2)) < 92%." | 5.10 | Discontinuation of furosemide decreases PaCO(2) in patients with COPD. ( Brijker, F; Folgering, HT; Heijdra, YF; van den Elshout, FJ, 2002) |
| "The aim of the study was to investigate pulmonary function parameters in patients who did and did not have pulmonary hypertension, and the roles of forced vital capacity (FVC)/diffusing capacity of the lungs for carbon monoxide (DLCO) and FVC/DLCO/alveolar volume (VA) values in patients with COPD accompanied by pulmonary hypertension." | 4.12 | Can FVC/DLCO predict pulmonary hypertension in patients with chronic obstructive pulmonary disease? ( Beyhan Sagmen, S; Fidan, A, 2022) |
| "PLWH and HIV-uninfected individuals were enrolled from 2 clinical centers and completed a 6-MWD, spirometry, diffusing capacity for carbon monoxide (DLCO) and St." | 3.91 | HIV infection is an independent risk factor for decreased 6-minute walk test distance. ( Chandra, D; Crothers, KA; Fitzpatrick, ME; Greenblatt, RM; Huang, L; Kessinger, CJ; Kingsley, LA; McMahon, D; Morris, A; Nouraie, M; Qin, S; Robertson, TE, 2019) |
| "We assumed that the level of expired-air carbon monoxide may not useful in assessing the severity of inflammation in COPD (Tab." | 3.74 | Does the expired-air carbon monoxide level reflect the severity of inflammation in COPD? ( Hanta, I; Kocabas, A; Olgunus, O; Satar, S; Seydaoglu, G, 2007) |
| " They had an unusual pattern of cardiopulmonary abnormalities with mild to moderate airway obstruction, severe hypoxemia, hypocapnia, and a very low diffusing capacity for carbon monoxide (p < 0." | 3.73 | Severe pulmonary hypertension and chronic obstructive pulmonary disease. ( Bugnet, AS; Chaouat, A; Ducoloné, A; Ehrhart, M; Enache, I; Kadaoui, N; Kessler, R; Schott, R; Weitzenblum, E, 2005) |
| " In multivariate analysis, chronic graft-versus-host disease (relative risk, 16) and pretransplantation diffusion capacity for carbon monoxide or forced expiratory volume in the first second <80% predicted were independently associated with a late decrease in PF from baseline (relative risk, 7)." | 3.73 | Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. ( Barrett, AJ; Childs, R; Karimpour, S; Mielke, S; Montero, A; Rezvani, K; Savani, BN; Shenoy, A; Singh, A; Srinivasan, R, 2006) |
| " The COPD patients were assigned to 2 groups based on the ratio of carbon monoxide diffusing capacity (DLCO) to alveolar volume (DLCO/VA) expressed as a percentage as follows: a) mainly emphysema (n = 15) and b) mainly chronic bronchitis (n = 24)." | 3.73 | [Systemic and lung inflammation in 2 phenotypes of chronic obstructive pulmonary disease]. ( Almonacid, C; Izquierdo, JL; Parra, T; Pérez, J, 2006) |
| "Three hundred thirty-one consecutive outpatients (161 with asthma and 170 with COPD) were examined cross-sectionally by self-reported smoking status, breath CO monitoring, and serum cotinine concentration." | 3.72 | Optimal cutoff level of breath carbon monoxide for assessing smoking status in patients with asthma and COPD. ( Hajiro, T; Koyama, H; Mishima, M; Nishimura, K; Oga, T; Sato, S; Tsukino, M, 2003) |
| "We studied patients with asthma or COPD from Czechia, Ireland, and Spain." | 3.01 | Lung function changes in patients with chronic obstructive pulmonary disease (COPD) and asthma exposed to secondhand smoke in outdoor areas. ( Alonso, T; Boffi, R; Clancy, L; Fernández, E; Gallus, S; Gorini, G; Keogan, S; López, MJ; López-Nicolás, Á; Radu-Loghin, C; Semple, S; Soriano, JB; Sunday, S; Tigova, O; Tzortzi, A, 2021) |
| "Rate of acceptance for COPD screening was 28% in the eCO group and 26% in the other (P = 0." | 2.80 | Is generalization of exhaled CO assessment in primary care helpful for early diagnosis of COPD? ( Abou-Badra, M; Amador, N; Bourdin, A; Gamez, AS; Ky, CL; Marin, G; Molinari, N; Vachier, I, 2015) |
| "In both COPD and healthy subjects, rapid saline infusion with placebo or salmeterol premedication lead to a significant decrease in diffusion capacity for carbon monoxide (DLCO) and forced expiratory volume in 1 s (FEV1)." | 2.77 | Salmeterol improves fluid clearance from alveolar-capillary membrane in COPD patients: a pilot study. ( Blasi, F; Busatto, P; Centanni, S; Di Marco, F; Guazzi, M; Piffer, F; Santus, P; Sferrazza Papa, GF; Vicenzi, M, 2012) |
| "Since chronic obstructive pulmonary disease (COPD) is characterised by inflammation and oxidative stress, low-dose CO could be of therapeutic use." | 2.73 | Anti-inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study. ( Bathoorn, E; Boezen, HM; Kerstjens, HA; Koeter, GH; Postma, DS; Slebos, DJ; van der Toorn, M; van Oosterhout, AJ, 2007) |
| "The elevated risk of chronic obstructive pulmonary disease in PWH has been widely recognized, but PWH are also at higher risk for asthma and worse asthma outcomes." | 2.72 | Recent advances in HIV-associated chronic lung disease clinical research. ( Kunisaki, KM, 2021) |
| "(2) There is a valid definition for COPD." | 2.49 | A challenge to the seven widely believed concepts of COPD. ( Al-Kassimi, FA; Alhamad, EH, 2013) |
| "Nicotine promotes physical addiction to tobacco as well as causes pulmonary diseases, cardiovascular diseases or cancers to smokers." | 2.49 | [Compounds in tobacco smoke and pathogenesis of the diseases]. ( Sasaki, J, 2013) |
| "Chronic obstructive pulmonary disease (COPD) is a disease involving airways restriction, alveolar destruction, and loss of lung function, primarily due to cigarette smoke (CS) exposure." | 2.48 | Heme Oxygenase-1/CO as protective mediators in cigarette smoke- induced lung cell injury and chronic obstructive pulmonary disease. ( Choi, AM; Dolinay, T; Ryter, SW, 2012) |
| "Alveolar NO is increased in chronic obstructive pulmonary disease (COPD), reflecting disease severity and progression." | 2.42 | Effects of corticosteroids on noninvasive biomarkers of inflammation in asthma and chronic obstructive pulmonary disease. ( Barnes, PJ; Kharitonov, SA, 2004) |
| "Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) patients experience exacerbations more frequently than those with asthma or COPD alone." | 1.72 | The association between transfer coefficient of the lung and the risk of exacerbation in asthma-COPD overlap: an observational cohort study. ( Aso, H; Enokizu-Ogawa, A; Ishimatsu, A; Jingushi, Y; Katahira, K; Moriwaki, A; Nogami, H; Ogata, H; Taguchi, K; Yoshida, M, 2022) |
| "Even among those without COPD, HIV was independently associated with lower DLCO (β -3." | 1.72 | Brief Report: HIV Is Associated With Impaired Pulmonary Diffusing Capacity Independent of Emphysema. ( Astemborski, J; Brown, RH; Drummond, MB; Kirk, GD; McCormack, MC; Raju, S; Ramamurthi, HC; Sun, J, 2022) |
| "Patients with COPD have an accelerated decline in Dlco compared with smokers without the disease." | 1.62 | Natural Course of the Diffusing Capacity of the Lungs for Carbon Monoxide in COPD: Importance of Sex. ( Amado, C; Balcells, E; Cabrera, C; Calle, M; Casanova, C; Celli, BR; Cosio, BG; de Torres, JP; Divo, M; Feu, N; Fuster, A; Golpe, R; Gonzalez-Dávila, E; López-Campos, JL; Marin, JM; Marín-Oto, M; Martínez-Gonzalez, C; Ojeda, E; Peces-Barba, G; Pinto-Plata, V; Solanes, I, 2021) |
| "GOLD stage I COPD patients (n = 360) were enrolled and followed over 109 ± 50 months." | 1.62 | Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD. ( Cabrera, C; Casanova, C; Celli, BR; Cosio, BG; de-Torres, JP; Ezponda, A; Fuster, A; Gonzalez-Gutierrez, J; Marín, JM; Marín, M; Martinez, C; Neder, JA; O'Donnell, DE; Solanes, I, 2021) |
| "Secondary polycythemia is associated with cigarette smoking and chronic obstructive pulmonary disease (COPD)." | 1.62 | Secondary polycythemia in chronic obstructive pulmonary disease: prevalence and risk factors. ( Cho, MH; DeMeo, DL; Hobbs, BD; Make, BJ; Silverman, EK; Wade, RC; Wells, JM; Zhang, J, 2021) |
| "Smoking cessation was achieved by varenicline plus individual counselling." | 1.56 | Effectiveness of smoking cessation in smokers with COPD and nocturnal oxygen desaturation: Functional analysis. ( Carico, E; Pezzuto, A, 2020) |
| "Chronic obstructive pulmonary disease (COPD) is characterized by systemic inflammation that usually is caused by exposure to noxious particles or gases." | 1.56 | The protective effects of thymoquinone on lung damage caused by cigarette smoke. ( Büyükoğlan, H; Gülmez, I; Sönmez, MF; Tutar, N; Yetkin, NA; Yilmaz, I, 2020) |
| "Chronic Obstructive Pulmonary Disease (COPD) is a common chronic respiratory disease related to inflammation affected by harmful gas and particulate matter in the air." | 1.56 | Predicting the morbidity of chronic obstructive pulmonary disease based on multiple locally weighted linear regression model with K-means clustering. ( Cao, JY; Gregersen, H; Huang, ZY; Lin, S; Long, LL; Luo, F; Qin, WC; Sun, DM, 2020) |
| "Out of the 155 COPD patients with nicotine dependence (female/male = 39/116; mean age, 67." | 1.56 | Outcomes and predictive factors for successful smoking cessation therapy in COPD patients with nicotine dependence. ( Hashimoto, R; Tomioka, H; Wada, T; Yoshizumi, Y, 2020) |
| "We hypothesized that in mild COPD, functional SAD (fSAD) defined by computed tomography (CT) and Parametric Response Mapping methodology would correlate with impaired DLCO." | 1.51 | Relationship between diffusion capacity and small airway abnormality in COPDGene. ( Casaburi, R; Criner, RN; Curtis, JL; Galbán, CJ; Han, MLK; Hatt, CR; Kazerooni, EA; Labaki, WW; Lynch, DA; MacIntyre, NR; Make, BJ; Martinez, FJ; McCormack, MC, 2019) |
| "Data for 1,806 participants with COPD from the Genetic Epidemiology of COPD (COPDGene) study 5-year visit were analyzed, including pulmonary function testing, quality of life, symptoms, exercise performance, and exacerbation rates." | 1.51 | Diffusing Capacity of Carbon Monoxide in Assessment of COPD. ( Balasubramanian, A; Barr, RG; Bowler, RP; Casaburi, R; Han, MK; Henderson, RJ; Hersh, CP; Jensen, RL; Kinney, G; MacIntyre, NR; Make, BJ; McCormack, MC; Porszasz, J; Stringer, WW; Wise, RA, 2019) |
| "The development of COPD features, such as an incomplete reversibility of airway obstruction (IRAO), in smoking or non-smoking asthmatic patients, a condition often named Asthma-COPD Overlap (ACO), has been recognized for decades." | 1.48 | Asthma-COPD Overlap Phenotypes and Smoking :Comparative features of asthma in smoking or non-smoking patients with an incomplete reversibility of airway obstruction. ( Bilodeau, L; Boulay, MÈ; Boulet, LP; Dérival, JL; Lepage, J; Maltais, F; Milot, J, 2018) |
| "Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease in which the amount of emphysema and airway disease may be very different between individuals, even in end-stage disease." | 1.46 | Hypoxic vascular response and ventilation/perfusion matching in end-stage COPD may depend on p22phox. ( Ghanim, B; Heschl, S; Jain, PP; Klepetko, W; Kwapiszewska, G; Marsh, LM; Nagaraj, C; Nagy, BM; Olschewski, A; Olschewski, H; Papp, R; Pienn, M; Tabeling, C; Weir, EK; Witzenrath, M, 2017) |
| "The analysis of data from a COPD cohort showed no significant differences of CO transport parameters between COPD patients with and without diabetes, if BMI, gender and the reduction in lung volumes were taken into account." | 1.46 | Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort. ( Alter, P; Bals, R; Behr, J; Biertz, F; Holle, R; Huber, RM; Jörres, RA; Kahnert, K; Karrasch, S; Lechner, A; Lucke, T; Söhler, S; Stubbe, B; Vogelmeier, C; Wacker, M; Watz, H; Wouters, EF, 2017) |
| "Patients with AECOPD were also stratified according to sputum bacteria." | 1.43 | Assessment of exhaled carbon monoxide in exacerbations of chronic obstructive pulmonary disease. ( Antus, B; Barta, I; Drozdovszky, O, 2016) |
| "CI difference (6." | 1.43 | [Use of COPD-6 Vitalograph in Primary Care as tool for smoking cessation]. ( Antón-García, F; Correcher-Salvador, E; Pruteanu, DF, 2016) |
| "To explore the use of the COPD-LUCSS using the DLCO instead of radiological emphysema, as a tool to identify patients with COPD at higher risk of LC death." | 1.43 | Identification of COPD Patients at High Risk for Lung Cancer Mortality Using the COPD-LUCSS-DLCO. ( Casanova, C; Celli, BR; Cote, C; de-Torres, JP; Divo, M; Marín, JM; Pinto-Plata, V; Zulueta, JJ, 2016) |
| "The origin of systemic inflammation in chronic obstructive pulmonary disease (COPD) patients remains to be defined, but one of the most widely accepted hypothesis is the 'spill over' of inflammatory mediators from the lung to the circulation." | 1.43 | Lack of Correlation Between Pulmonary and Systemic Inflammation Markers in Patients with Chronic Obstructive Pulmonary Disease: A Simultaneous, Two-Compartmental Analysis. ( Agusti, A; Antó, JM; Barreiro, E; Garcia-Aymerich, J; Gómez, F; Marín, A; Monsó, E; Noguera, A; Núñez, B; Sauleda, J, 2016) |
| "Chronic obstructive pulmonary disease (COPD) is a prevalent condition in adults aged ≥40 years characterized by progressive airflow limitation associated with chronic inflammatory response to noxious particles in the airways and lungs." | 1.43 | Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): An Ecological Study in the Basque Country, Spain (2000-2011). ( Altzibar, JM; Dorronsoro, M; Mughini-Gras, L; Tamayo-Uria, I, 2016) |
| "Smokers are assessed for chronic obstructive pulmonary disease (COPD) using spirometry, with COPD defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) as airflow limitation that is not fully reversible with bronchodilators." | 1.42 | Risk of COPD with obstruction in active smokers with normal spirometry and reduced diffusion capacity. ( Crystal, RG; Harvey, BG; Kaner, RJ; Mezey, JG; Sanders, A; Strulovici-Barel, Y; Vincent, TL, 2015) |
| "Hospital admissions for RD including chronic obstructive pulmonary disease (COPD), asthma, and pneumonia, and ambient air pollution data levels for Kaohsiung were obtained for the period from 2006 to 2010." | 1.42 | Coarse Particulate Air Pollution Associated with Increased Risk of Hospital Admissions for Respiratory Diseases in a Tropical City, Kaohsiung, Taiwan. ( Cheng, MH; Chiu, HF; Yang, CY, 2015) |
| "We assessed 121 COPD subjects during 2 years using clinical variables, computed tomographic (CT) measures of emphysema, and functional measures including diffusion lung capacity for carbon monoxide (DLCO)." | 1.42 | Emphysema and DLCO predict a clinically important difference for 6MWD decline in COPD. ( Díaz, AA; Díaz, JC; Díaz, O; Hernández, C; Klaassen, J; Patino, CM; Peña, J; Pinto-Plata, V; Ramos, C; Saldías, F, 2015) |
| "Daily data on COPD admissions and CO concentrations between 2006 and 2008 were collected." | 1.42 | Does ambient CO have protective effect for COPD patient? ( Cai, J; Chen, R; Ha, S; Kan, H; Wang, W; Xu, X, 2015) |
| "Briefly, severe and very severe chronic obstructive pulmonary disease (COPD) patients who were candidate for volume reduction surgery and who could provide sufficient data at 12-month follow-up were included." | 1.42 | Minimum clinically important difference in diffusing capacity of the lungs for carbon monoxide among patients with severe and very severe chronic obstructive pulmonary disease. ( Horita, N; Inoue, M; Ishigatsubo, Y; Kaneko, T; Kojima, R; Miyazawa, N, 2015) |
| "Acute exacerbations of COPD (AECOPD) are important events during disease procedure." | 1.42 | A GIS-based spatial correlation analysis for ambient air pollution and AECOPD hospitalizations in Jinan, China. ( Ma, D; Wang, W; Wu, Q; Xiao, W; Ying, Y; Zhang, H, 2015) |
| "From CSSR acquisitions, the COPD subjects showed red blood cell to tissue-plasma (RBC-to-TP) ratios below the average for the healthy subjects (p < 0." | 1.40 | Assessment of lung function in asthma and COPD using hyperpolarized 129Xe chemical shift saturation recovery spectroscopy and dissolved-phase MRI. ( Altes, TA; Hersman, FW; Jiang, Y; Mata, JF; Miller, GW; Mugler, JP; Qing, K; Ruppert, K; Ruset, IC, 2014) |
| "Airway obstruction was identified by spirometry in only 67% of individuals diagnosed with COPD." | 1.40 | The impact of deployment on COPD in active duty military personnel. ( Abraham, J; Matthews, T; Morris, MJ; Zacher, LL, 2014) |
| "Exercise intolerance is a hallmark of chronic obstructive pulmonary disease (COPD) and forced expiratory volume in one second (FEV1) is the traditional metric used to define the severity of COPD." | 1.39 | Impaired carbon monoxide diffusing capacity is the strongest predictor of exercise intolerance in COPD. ( Arnardóttir, RH; Emtner, M; Farkhooy, A; Hedenström, H; Janson, C; Malinovschi, A, 2013) |
| "We included 30 men with COPD (normal aBMD, n = 18; osteoporosis, n = 12) and 17 men without COPD (normal aBMD, n = 9; osteoporosis, n = 8)." | 1.39 | Bone stiffness and failure load are related with clinical parameters in men with chronic obstructive pulmonary disease. ( de Jong, JJ; Geusens, P; Romme, EA; Rutten, EP; Smeenk, FW; van den Bergh, JP; van Rietbergen, B; Wouters, EF, 2013) |
| "Of 38 ex-smokers without COPD, 19 subjects had abnormal DLCO with significantly worse ADC (p=0." | 1.39 | On the role of abnormal DL(CO) in ex-smokers without airflow limitation: symptoms, exercise capacity and hyperpolarised helium-3 MRI. ( Coxson, HO; Kirby, M; McCormack, DG; Owrangi, A; Parraga, G; Paterson, NA; Svenningsen, S; Wheatley, A, 2013) |
| "The test time of re-breathing in the COPD group (106 ± 5) s was significant longer than that of the ILD group (73 ± 4) s and the control group (79 ± 5) s (F = 11." | 1.39 | [Single-breath and rebreathing methods for measurement of pulmonary diffusing function: a comparative study]. ( An, JY; Gao, Y; Guan, WJ; Jiang, CY; Liu, QX; Liu, WT; Xie, YQ; Yu, XX; Zheng, JP, 2013) |
| "We included 154 patients with COPD (87 females)." | 1.38 | Prevalence and prediction of exercise-induced oxygen desaturation in patients with chronic obstructive pulmonary disease. ( Clarenbach, CF; Kohler, M; Russi, EW; Stöwhas, AC; Teschler, H; Teschler, S; van Gestel, AJ, 2012) |
| "Individuals with COPD had higher CO levels than healthy individuals." | 1.37 | Validation of the respiratory toxics exposure score (RTES) for chronic obstructive pulmonary disease screening. ( Khayat, G; Salameh, P; Waked, M, 2011) |
| "We included 288 COPD subjects (70% men) and 425 non-COPD subjects (54% men)." | 1.37 | Quantitative CT measures of emphysema and airway wall thickness are related to D(L)CO. ( Bakke, PS; Coxson, HO; Dirksen, A; Eide, GE; Grydeland, TB; Gulsvik, A; Jensen, R; Pillai, SG; Sharma, S; Thorsen, E, 2011) |
| "Pulmonary hypertension was the most frequent condition associated with Kco severe reduction." | 1.37 | Conditions associated with severe carbon monoxide diffusion coefficient reduction. ( Bayle, JY; Cordier, JF; Cottin, V; Glerant, JC; Kiakouama, L; Mornex, JF, 2011) |
| "Patients in asthma or COPD exacerbations were evaluated twice-during the exacerbation and at a follow-up visit-to compare variations in breath biomarkers during these events." | 1.37 | Clinical study of multiple breath biomarkers of asthma and COPD (NO, CO(2), CO and N(2)O) by infrared laser spectroscopy. ( McManus, JB; Milton, DK; Nelson, DD; Sama, SR; Shorter, JH; Zahniser, MS, 2011) |
| "Emphysema has been diagnosed at 22 women (11-50% active smokers, 3-13." | 1.35 | Comparison assessment methods of smoking consequences use in primary care. ( Kałucka, S, 2009) |
| "Patients with chronic obstructive pulmonary disease (COPD) can have recurrent disease exacerbations triggered by several factors, including air pollution." | 1.35 | Urban air pollution and chronic obstructive pulmonary disease-related emergency department visits. ( Arbex, FF; Arbex, MA; Braga, AL; Cendon, SP; de Souza Conceição, GM; Lopes, AC; Moysés, EP; Pereira, LA; Saldiva, PH; Santiago, SL, 2009) |
| "The diagnosis of chronic obstructive pulmonary disease (COPD) relies on the presence of chronic airflow limitation poorly reversible or not reversible at all, defined by an FEV1/FVC ratio less than 70%." | 1.35 | [Pulmonary function tests in chronic obstructive pulmonary disease]. ( Canuet, M; Chaouat, A; Kessler, R; Weitzenblum, E, 2009) |
| "Hospital admissions for COPD and ambient air pollution data for Kaohsiung were obtained for the period from 1996 to 2003." | 1.34 | Air pollution and hospital admissions for chronic obstructive pulmonary disease in a tropical city: Kaohsiung, Taiwan. ( Chang, CC; Ho, CK; Lee, IM; Tsai, SS; Yang, CY, 2007) |
| "A total of 20 COPD patients (mean age 57 yrs, range 49-69) with a median (interquartile range) forced expiratory volume in one second (FEV1) of 51 (33-69)% predicted underwent BAL." | 1.33 | Bronchoalveolar lavage in COPD: fluid recovery correlates with the degree of emphysema. ( Cederlund, K; Eklund, A; Löfdahl, JM; Nathell, L; Sköld, CM, 2005) |
| "Progression of chronic obstructive pulmonary disease (COPD) has been studied predominantly by following change in forced expiratory volume in 1s (FEV1) which reflects both primary airway disease and associated alveolar disease." | 1.33 | Evolution of changes in carbon monoxide transfer factor in men with chronic obstructive pulmonary disease. ( Joyce, H; Osmanliev, DP; Pride, NB; Watson, RA, 2005) |
| "The association between weight loss and Chronic Obstructive Pulmonary Disease (COPD) has been recognised from many years." | 1.33 | Nutritional status and airflow obstruction: two independent contributors to CO diffusing capacity impairment in COPD. ( Baldi, S; Bruschi, C; Crotti, P; Dacosto, E; Fanfulla, F; Fracchia, C; Montemartini, S; Pinna, GD, 2005) |
| "Ambient pollution might worsen chronic obstructive pulmonary disease (COPD)." | 1.33 | Winter air pollution and disease parameters in advanced chronic obstructive pulmonary disease panels residing in Denver, Colorado. ( Dutton, S; Langmack, EL; Make, B; Murphy, J; Silkoff, PE; Vedal, S; Zhang, L, 2005) |
| "Between 15% and 20% of smokers develop chronic obstructive pulmonary disease (COPD)." | 1.32 | Can cumulative tobacco consumption, FTND score, and carbon monoxide concentration in expired air be predictors of chronic obstructive pulmonary disease? ( Fernández-Fau, L; Gabriel, R; Jiménez-Ruiz, C; Masa, JF; Miravitlles, M; Sobradillo, V; Viejo, JL; Villasante, C, 2004) |
| "In 16 patients with chronic obstructive pulmonary disease (COPD) we investigated the relation between unequal ventilation and diffusion by means of lung volumes and Krogh factors (K(CO)) using the single breath (SB) and the rebreathing (RB) methods." | 1.31 | Influence of unequal ventilation on the single breath K(CO) in COPD revealed by comparison with the rebreathing K(CO). ( Fokkens, JK; Folgering, H; Jansons, H; Lammers, JW; Tweel van der, I, 2002) |
| "Alpha(1)-AT-deficient and COPD patients had lower exhaled CO(2) than controls, although only alpha(1)-AT-deficient patients had higher exhaled O(2) than healthy controls." | 1.31 | Low levels of nitric oxide and carbon monoxide in alpha 1-antitrypsin deficiency. ( Dweik, RA; Erzurum, SC; Laskowski, D; Lupica, JA; Machado, RF; Stoller, JK; Zheng, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 42 (30.22) | 29.6817 |
| 2010's | 70 (50.36) | 24.3611 |
| 2020's | 27 (19.42) | 2.80 |
| Authors | Studies |
|---|---|
| Raju, S | 1 |
| Astemborski, J | 1 |
| Drummond, MB | 1 |
| Ramamurthi, HC | 1 |
| Sun, J | 1 |
| Brown, RH | 1 |
| Kirk, GD | 1 |
| McCormack, MC | 4 |
| Ogata, H | 1 |
| Katahira, K | 1 |
| Enokizu-Ogawa, A | 1 |
| Jingushi, Y | 1 |
| Ishimatsu, A | 1 |
| Taguchi, K | 1 |
| Nogami, H | 1 |
| Aso, H | 1 |
| Moriwaki, A | 1 |
| Yoshida, M | 1 |
| Zhang, K | 2 |
| Zou, X | 1 |
| Ma, Z | 1 |
| Liu, X | 1 |
| Qiu, C | 1 |
| Xie, L | 1 |
| Lin, Z | 1 |
| Li, S | 1 |
| Wu, Y | 3 |
| Gülhan, PY | 1 |
| Arbak, PM | 1 |
| Annakkaya, AN | 1 |
| Balbay, EG | 1 |
| Balbay, ÖA | 1 |
| Beyhan Sagmen, S | 1 |
| Fidan, A | 1 |
| Peng, J | 1 |
| Wang, M | 1 |
| Shen, Y | 1 |
| Chen, L | 1 |
| Garcia-Rio, F | 1 |
| Miravitlles, M | 3 |
| Soriano, JB | 3 |
| Cosío, BG | 3 |
| Soler-Cataluña, JJ | 1 |
| Casanova, C | 4 |
| de Lucas, P | 1 |
| Alfageme, I | 1 |
| Rodríguez González-Moro, JM | 1 |
| Sánchez Herrero, MG | 1 |
| Ancochea, J | 1 |
| Song, J | 1 |
| Qiu, W | 1 |
| Huang, X | 1 |
| Guo, Y | 2 |
| Chen, W | 1 |
| Wang, D | 1 |
| Zhang, X | 1 |
| Dimic-Janjic, S | 1 |
| Hoda, MA | 1 |
| Milenkovic, B | 1 |
| Kotur-Stevuljevic, J | 1 |
| Stjepanovic, M | 1 |
| Gompelmann, D | 1 |
| Jankovic, J | 1 |
| Miljkovic, M | 1 |
| Milin-Lazovic, J | 1 |
| Djurdjevic, N | 1 |
| Maric, D | 1 |
| Milivojevic, I | 1 |
| Popevic, S | 1 |
| Byanova, KL | 1 |
| Fitzpatrick, J | 1 |
| Jan, AK | 1 |
| McGing, M | 1 |
| Hartman-Filson, M | 1 |
| Farr, CK | 1 |
| Zhang, M | 1 |
| Gardner, K | 1 |
| Branchini, J | 1 |
| Kerruish, R | 1 |
| Bhide, S | 1 |
| Bates, A | 1 |
| Hsieh, J | 1 |
| Abelman, R | 1 |
| Hunt, PW | 1 |
| Wang, RJ | 1 |
| Crothers, KA | 2 |
| Huang, L | 3 |
| Liu, Y | 2 |
| You, J | 1 |
| Dong, J | 1 |
| Wang, J | 1 |
| Bao, H | 1 |
| Pezzuto, A | 2 |
| Carico, E | 1 |
| Yetkin, NA | 1 |
| Büyükoğlan, H | 1 |
| Sönmez, MF | 1 |
| Tutar, N | 1 |
| Gülmez, I | 1 |
| Yilmaz, I | 1 |
| Criner, RN | 1 |
| Hatt, CR | 1 |
| Galbán, CJ | 1 |
| Kazerooni, EA | 1 |
| Lynch, DA | 2 |
| Casaburi, R | 2 |
| MacIntyre, NR | 2 |
| Make, BJ | 3 |
| Martinez, FJ | 1 |
| Labaki, WW | 1 |
| Curtis, JL | 1 |
| Han, MLK | 1 |
| Qin, S | 2 |
| Vodovotz, L | 1 |
| Zamora, R | 1 |
| Fitzpatrick, M | 1 |
| Kessinger, C | 1 |
| Kingsley, L | 1 |
| McMahon, D | 2 |
| DeSensi, R | 1 |
| Leader, JK | 1 |
| Crothers, K | 1 |
| Morris, A | 3 |
| Nouraie, M | 3 |
| Raji, H | 1 |
| Riahi, A | 1 |
| Borsi, SH | 1 |
| Masoumi, K | 1 |
| Khanjani, N | 1 |
| AhmadiAngali, K | 1 |
| Goudarzi, G | 1 |
| Dastoorpoor, M | 1 |
| Kunisaki, KM | 2 |
| Jensen, RL | 2 |
| Chang, D | 1 |
| D'Souza, G | 1 |
| Fitzpatrick, ME | 2 |
| Stosor, V | 1 |
| Huang, ZY | 1 |
| Lin, S | 1 |
| Long, LL | 1 |
| Cao, JY | 1 |
| Luo, F | 1 |
| Qin, WC | 1 |
| Sun, DM | 1 |
| Gregersen, H | 1 |
| Hashimoto, R | 1 |
| Tomioka, H | 1 |
| Wada, T | 1 |
| Yoshizumi, Y | 1 |
| Keogan, S | 1 |
| Alonso, T | 1 |
| Sunday, S | 1 |
| Tigova, O | 1 |
| Fernández, E | 1 |
| López, MJ | 1 |
| Gallus, S | 1 |
| Semple, S | 1 |
| Tzortzi, A | 1 |
| Boffi, R | 1 |
| Gorini, G | 1 |
| López-Nicolás, Á | 1 |
| Radu-Loghin, C | 1 |
| Clancy, L | 1 |
| Chaouat, A | 3 |
| Adir, Y | 1 |
| Ohara, A | 1 |
| Konno, S | 1 |
| Shimizu, K | 1 |
| Suzuki, M | 1 |
| Yamamoto, M | 1 |
| Mitani, A | 1 |
| Nishida, M | 1 |
| Teshima, T | 1 |
| Nishimura, M | 1 |
| Tanabe, N | 1 |
| Rhee, CK | 2 |
| Sato, S | 2 |
| Muro, S | 1 |
| Shima, H | 1 |
| Tanimura, K | 1 |
| Jung, KS | 1 |
| Yoo, KH | 1 |
| Hirai, T | 1 |
| Gonzalez-Dávila, E | 1 |
| Martínez-Gonzalez, C | 1 |
| Fuster, A | 2 |
| Feu, N | 1 |
| Solanes, I | 2 |
| Cabrera, C | 2 |
| Marin, JM | 3 |
| Balcells, E | 1 |
| Peces-Barba, G | 1 |
| de Torres, JP | 1 |
| Marín-Oto, M | 1 |
| Calle, M | 1 |
| Golpe, R | 1 |
| Ojeda, E | 1 |
| Divo, M | 2 |
| Pinto-Plata, V | 3 |
| Amado, C | 1 |
| López-Campos, JL | 1 |
| Celli, BR | 3 |
| de-Torres, JP | 2 |
| O'Donnell, DE | 1 |
| Marín, M | 1 |
| Ezponda, A | 1 |
| Martinez, C | 1 |
| Neder, JA | 1 |
| Gonzalez-Gutierrez, J | 1 |
| Choi, J | 1 |
| Sim, JK | 1 |
| Oh, JY | 1 |
| Lee, YS | 1 |
| Hur, GY | 1 |
| Lee, SY | 1 |
| Shim, JJ | 1 |
| Min, KH | 1 |
| Zhang, J | 1 |
| DeMeo, DL | 1 |
| Silverman, EK | 1 |
| Wade, RC | 1 |
| Wells, JM | 1 |
| Cho, MH | 1 |
| Hobbs, BD | 1 |
| Di Marco, F | 2 |
| Terraneo, S | 1 |
| Job, S | 1 |
| Rinaldo, RF | 1 |
| Sferrazza Papa, GF | 2 |
| Roggi, MA | 1 |
| Santus, P | 2 |
| Centanni, S | 2 |
| Greening, NJ | 1 |
| Vaughan, P | 1 |
| Oey, I | 1 |
| Steiner, MC | 1 |
| Morgan, MD | 1 |
| Rathinam, S | 1 |
| Waller, DA | 1 |
| Antus, B | 1 |
| Drozdovszky, O | 1 |
| Barta, I | 1 |
| Nagaraj, C | 1 |
| Tabeling, C | 1 |
| Nagy, BM | 1 |
| Jain, PP | 1 |
| Marsh, LM | 1 |
| Papp, R | 1 |
| Pienn, M | 1 |
| Witzenrath, M | 1 |
| Ghanim, B | 1 |
| Klepetko, W | 1 |
| Weir, EK | 1 |
| Heschl, S | 1 |
| Kwapiszewska, G | 1 |
| Olschewski, A | 1 |
| Olschewski, H | 1 |
| Du Plessis, JP | 1 |
| Fernandes, S | 1 |
| Jamal, R | 1 |
| Camp, P | 1 |
| Johannson, K | 1 |
| Schaeffer, M | 1 |
| Wilcox, PG | 1 |
| Guenette, JA | 1 |
| Ryerson, CJ | 1 |
| Hsu, K | 1 |
| Williamson, JP | 1 |
| Peters, MJ | 1 |
| Ing, AJ | 1 |
| Nie, D | 1 |
| Chen, M | 1 |
| Ge, X | 1 |
| Hu, J | 1 |
| Ge, P | 1 |
| Boulet, LP | 1 |
| Boulay, MÈ | 1 |
| Dérival, JL | 1 |
| Milot, J | 1 |
| Lepage, J | 1 |
| Bilodeau, L | 1 |
| Maltais, F | 1 |
| Serban, KA | 1 |
| Petrache, I | 1 |
| Westcott, A | 1 |
| Capaldi, DPI | 1 |
| Ouriadov, A | 1 |
| McCormack, DG | 2 |
| Parraga, G | 2 |
| Hernández Zenteno, RJ | 1 |
| Lara, DF | 1 |
| Venegas, AR | 1 |
| Sansores, RH | 1 |
| Pineda, JR | 1 |
| Trujillo, FF | 1 |
| Pérez Padilla, JR | 1 |
| Matera, MG | 1 |
| Cazzola, M | 1 |
| Kaminsky, DA | 1 |
| Jarzembowski, SC | 1 |
| Robertson, TE | 1 |
| Kessinger, CJ | 1 |
| Chandra, D | 1 |
| Kingsley, LA | 1 |
| Greenblatt, RM | 1 |
| Kis, A | 1 |
| Meszaros, M | 1 |
| Tarnoki, DL | 1 |
| Tarnoki, AD | 1 |
| Lazar, Z | 1 |
| Horvath, P | 1 |
| Kunos, L | 1 |
| Bikov, A | 1 |
| Balasubramanian, A | 1 |
| Henderson, RJ | 1 |
| Kinney, G | 1 |
| Stringer, WW | 1 |
| Hersh, CP | 1 |
| Bowler, RP | 1 |
| Han, MK | 1 |
| Porszasz, J | 1 |
| Barr, RG | 1 |
| Wise, RA | 1 |
| Ryter, SW | 2 |
| Choi, AM | 2 |
| Farkhooy, A | 2 |
| Janson, C | 2 |
| Arnardóttir, RH | 2 |
| Malinovschi, A | 2 |
| Emtner, M | 2 |
| Hedenström, H | 2 |
| Romme, EA | 1 |
| Rutten, EP | 1 |
| Geusens, P | 1 |
| de Jong, JJ | 1 |
| van Rietbergen, B | 1 |
| Smeenk, FW | 1 |
| Wouters, EF | 3 |
| van den Bergh, JP | 1 |
| Kirby, M | 1 |
| Owrangi, A | 1 |
| Svenningsen, S | 1 |
| Wheatley, A | 1 |
| Coxson, HO | 2 |
| Paterson, NA | 1 |
| Sasaki, J | 1 |
| Kawut, SM | 1 |
| Zhang, Q | 1 |
| Li, L | 1 |
| Smith, M | 1 |
| Whitlock, G | 1 |
| Bian, Z | 1 |
| Kurmi, O | 1 |
| Collins, R | 1 |
| Chen, J | 1 |
| Lv, S | 1 |
| Pang, Z | 1 |
| Chen, C | 1 |
| Chen, N | 1 |
| Xiong, Y | 1 |
| Peto, R | 1 |
| Chen, Z | 1 |
| Spoto, C | 1 |
| Vincenzi, B | 1 |
| Tonini, G | 1 |
| Liu, QX | 1 |
| Zheng, JP | 1 |
| Xie, YQ | 1 |
| Guan, WJ | 1 |
| Jiang, CY | 1 |
| An, JY | 1 |
| Yu, XX | 1 |
| Liu, WT | 1 |
| Gao, Y | 2 |
| Furlanetto, KC | 1 |
| Mantoani, LC | 1 |
| Bisca, G | 1 |
| Morita, AA | 1 |
| Zabatiero, J | 1 |
| Proença, M | 1 |
| Kovelis, D | 1 |
| Pitta, F | 1 |
| Guarnieri, MJ | 1 |
| Diaz, JV | 1 |
| Basu, C | 1 |
| Diaz, A | 1 |
| Pope, D | 1 |
| Smith, KR | 1 |
| Smith-Sivertsen, T | 1 |
| Bruce, N | 1 |
| Solomon, C | 1 |
| McCracken, J | 1 |
| Balmes, JR | 1 |
| Horita, N | 1 |
| Miyazawa, N | 1 |
| Kojima, R | 1 |
| Inoue, M | 1 |
| Ishigatsubo, Y | 1 |
| Kaneko, T | 1 |
| Maddocks, M | 1 |
| Shrikrishna, D | 1 |
| Vitoriano, S | 1 |
| Natanek, SA | 1 |
| Tanner, RJ | 1 |
| Hart, N | 1 |
| Kemp, PR | 1 |
| Moxham, J | 1 |
| Polkey, MI | 1 |
| Hopkinson, NS | 1 |
| Bloom, AJ | 1 |
| Hartz, SM | 1 |
| Baker, TB | 1 |
| Chen, LS | 1 |
| Piper, ME | 1 |
| Fox, L | 1 |
| Martinez, M | 1 |
| Hatsukami, D | 1 |
| Johnson, EO | 1 |
| Laurie, CC | 1 |
| Saccone, NL | 1 |
| Goate, A | 1 |
| Bierut, LJ | 1 |
| Husemann, K | 1 |
| Berg, N | 1 |
| Engel, J | 1 |
| Port, J | 1 |
| Joppek, C | 1 |
| Tao, Z | 1 |
| Singer, F | 1 |
| Schulz, H | 1 |
| Kohlhäufl, M | 1 |
| Qing, K | 1 |
| Mugler, JP | 1 |
| Altes, TA | 1 |
| Jiang, Y | 1 |
| Mata, JF | 1 |
| Miller, GW | 1 |
| Ruset, IC | 1 |
| Hersman, FW | 1 |
| Ruppert, K | 1 |
| Matthews, T | 1 |
| Abraham, J | 1 |
| Zacher, LL | 1 |
| Morris, MJ | 1 |
| Cai, J | 1 |
| Chen, R | 1 |
| Wang, W | 2 |
| Xu, X | 1 |
| Ha, S | 1 |
| Kan, H | 1 |
| Tian, L | 1 |
| Ho, KF | 1 |
| Wang, T | 1 |
| Qiu, H | 1 |
| Pun, VC | 1 |
| Chan, CS | 1 |
| Louie, PK | 1 |
| Yu, IT | 1 |
| Ying, Y | 1 |
| Wu, Q | 1 |
| Zhang, H | 1 |
| Ma, D | 1 |
| Xiao, W | 1 |
| Nambu, A | 1 |
| Zach, J | 1 |
| Schroeder, J | 1 |
| Jin, GY | 1 |
| Kim, SS | 1 |
| Kim, YI | 1 |
| Schnell, C | 1 |
| Bowler, R | 1 |
| Bentayeb, M | 1 |
| Norback, D | 1 |
| Bednarek, M | 1 |
| Bernard, A | 1 |
| Cai, G | 1 |
| Cerrai, S | 1 |
| Eleftheriou, KK | 1 |
| Gratziou, C | 1 |
| Holst, GJ | 1 |
| Lavaud, F | 1 |
| Nasilowski, J | 1 |
| Sestini, P | 1 |
| Sarno, G | 1 |
| Sigsgaard, T | 1 |
| Wieslander, G | 1 |
| Zielinski, J | 1 |
| Viegi, G | 1 |
| Annesi-Maesano, I | 1 |
| Antón-García, F | 1 |
| Pruteanu, DF | 1 |
| Correcher-Salvador, E | 1 |
| Dogan, NÖ | 1 |
| Corbacioglu, SK | 1 |
| Bildik, F | 1 |
| Kilicaslan, I | 1 |
| Günaydin, GP | 1 |
| Cevik, Y | 1 |
| Ülker, V | 1 |
| Hakoglu, O | 1 |
| Gökcen, E | 1 |
| Molinari, N | 1 |
| Abou-Badra, M | 1 |
| Marin, G | 1 |
| Ky, CL | 1 |
| Amador, N | 1 |
| Gamez, AS | 1 |
| Vachier, I | 1 |
| Bourdin, A | 1 |
| Díaz, AA | 1 |
| Hernández, C | 1 |
| Peña, J | 1 |
| Ramos, C | 1 |
| Díaz, JC | 1 |
| Klaassen, J | 1 |
| Patino, CM | 1 |
| Saldías, F | 1 |
| Díaz, O | 1 |
| Weinreich, UM | 1 |
| Thomsen, LP | 1 |
| Brock, C | 1 |
| Karbing, DS | 1 |
| Rees, SE | 1 |
| Cheng, MH | 1 |
| Chiu, HF | 1 |
| Yang, CY | 2 |
| Cote, C | 1 |
| Zulueta, JJ | 1 |
| Harvey, BG | 1 |
| Strulovici-Barel, Y | 1 |
| Kaner, RJ | 1 |
| Sanders, A | 1 |
| Vincent, TL | 1 |
| Mezey, JG | 1 |
| Crystal, RG | 1 |
| Núñez, B | 1 |
| Sauleda, J | 1 |
| Garcia-Aymerich, J | 1 |
| Noguera, A | 1 |
| Monsó, E | 1 |
| Gómez, F | 1 |
| Barreiro, E | 1 |
| Marín, A | 1 |
| Antó, JM | 1 |
| Agusti, A | 1 |
| Obeidat, M | 1 |
| Ding, X | 1 |
| Fishbane, N | 1 |
| Hollander, Z | 1 |
| Ng, RT | 1 |
| McManus, B | 1 |
| Tebbutt, SJ | 1 |
| Miller, BE | 1 |
| Rennard, S | 1 |
| Paré, PD | 1 |
| Sin, DD | 1 |
| Tamayo-Uria, I | 1 |
| Altzibar, JM | 1 |
| Mughini-Gras, L | 1 |
| Dorronsoro, M | 1 |
| Garcia-Olive, I | 1 |
| Radua, J | 1 |
| Fiz, JA | 1 |
| Sanz-Santos, J | 1 |
| Ruiz-Manzano, J | 1 |
| Liang, M | 1 |
| Jiang, Z | 1 |
| Huang, Q | 1 |
| Liu, L | 1 |
| Xue, Y | 1 |
| Zhu, X | 1 |
| Yu, Y | 1 |
| Wan, W | 1 |
| Yang, H | 1 |
| Zou, H | 1 |
| Li, R | 1 |
| Jiang, N | 1 |
| Liu, Q | 1 |
| Huang, J | 1 |
| Guo, X | 1 |
| Liu, F | 1 |
| Gao, Z | 1 |
| Kahnert, K | 1 |
| Lucke, T | 1 |
| Biertz, F | 1 |
| Lechner, A | 1 |
| Watz, H | 1 |
| Alter, P | 1 |
| Bals, R | 1 |
| Behr, J | 1 |
| Holle, R | 1 |
| Huber, RM | 1 |
| Karrasch, S | 1 |
| Stubbe, B | 1 |
| Wacker, M | 1 |
| Söhler, S | 1 |
| Vogelmeier, C | 1 |
| Jörres, RA | 1 |
| Terzano, C | 1 |
| Conti, V | 1 |
| Petroianni, A | 1 |
| Ceccarelli, D | 1 |
| De Vito, C | 1 |
| Villari, P | 1 |
| Burtscher, M | 1 |
| Haider, T | 1 |
| Domej, W | 1 |
| Linser, T | 1 |
| Gatterer, H | 1 |
| Faulhaber, M | 1 |
| Pocecco, E | 1 |
| Ehrenburg, I | 1 |
| Tkatchuk, E | 1 |
| Koch, R | 1 |
| Bernardi, L | 1 |
| Weitzenblum, E | 2 |
| Canuet, M | 1 |
| Kessler, R | 2 |
| Hegewald, MJ | 1 |
| Vos, R | 1 |
| Cordemans, C | 1 |
| Vanaudenaerde, BM | 1 |
| De Vleeschauwer, SI | 1 |
| Schoonis, A | 1 |
| Van Raemdonck, DE | 1 |
| Dupont, LJ | 1 |
| Verleden, GM | 1 |
| Arbex, MA | 1 |
| de Souza Conceição, GM | 1 |
| Cendon, SP | 1 |
| Arbex, FF | 1 |
| Lopes, AC | 1 |
| Moysés, EP | 1 |
| Santiago, SL | 1 |
| Saldiva, PH | 1 |
| Pereira, LA | 1 |
| Braga, AL | 1 |
| Brüske, I | 1 |
| Hampel, R | 1 |
| Socher, MM | 1 |
| Rückerl, R | 1 |
| Schneider, A | 1 |
| Heinrich, J | 1 |
| Oberdörster, G | 1 |
| Wichmann, HE | 1 |
| Peters, A | 1 |
| Kałucka, S | 1 |
| Torchio, R | 1 |
| Guglielmo, M | 1 |
| Giardino, R | 1 |
| Ardissone, F | 1 |
| Ciacco, C | 1 |
| Gulotta, C | 1 |
| Veljkovic, A | 1 |
| Bugiani, M | 1 |
| Martinet, Y | 1 |
| Wirth, N | 1 |
| Brunelli, A | 1 |
| Grydeland, TB | 1 |
| Thorsen, E | 1 |
| Dirksen, A | 1 |
| Jensen, R | 1 |
| Pillai, SG | 1 |
| Sharma, S | 1 |
| Eide, GE | 2 |
| Gulsvik, A | 2 |
| Bakke, PS | 2 |
| Kiakouama, L | 1 |
| Cottin, V | 1 |
| Glerant, JC | 1 |
| Bayle, JY | 1 |
| Mornex, JF | 1 |
| Cordier, JF | 1 |
| Budinger, GR | 1 |
| Mutlu, GM | 1 |
| Shorter, JH | 1 |
| Nelson, DD | 1 |
| McManus, JB | 1 |
| Zahniser, MS | 1 |
| Sama, SR | 1 |
| Milton, DK | 1 |
| Salameh, P | 1 |
| Khayat, G | 1 |
| Waked, M | 1 |
| Gasior, N | 1 |
| David, M | 1 |
| Millet, V | 1 |
| Reynaud-Gaubert, M | 1 |
| Dubus, JC | 1 |
| Sandberg, A | 1 |
| Sköld, CM | 2 |
| Grunewald, J | 1 |
| Eklund, A | 2 |
| Wheelock, ÅM | 1 |
| Dolinay, T | 1 |
| Guazzi, M | 1 |
| Vicenzi, M | 1 |
| Busatto, P | 1 |
| Piffer, F | 1 |
| Blasi, F | 1 |
| van Gestel, AJ | 1 |
| Clarenbach, CF | 1 |
| Stöwhas, AC | 1 |
| Teschler, S | 1 |
| Russi, EW | 1 |
| Teschler, H | 1 |
| Kohler, M | 1 |
| Zhou, M | 1 |
| Duan, Y | 1 |
| Al-Kassimi, FA | 1 |
| Alhamad, EH | 1 |
| Wang, G | 1 |
| Qian, G | 1 |
| Mao, B | 1 |
| Dempsey, JA | 1 |
| Jansons, H | 1 |
| Fokkens, JK | 1 |
| Tweel van der, I | 1 |
| Lammers, JW | 1 |
| Folgering, H | 1 |
| Machado, RF | 1 |
| Stoller, JK | 1 |
| Laskowski, D | 1 |
| Zheng, S | 1 |
| Lupica, JA | 1 |
| Dweik, RA | 1 |
| Erzurum, SC | 1 |
| Paredi, P | 1 |
| Kharitonov, SA | 2 |
| Barnes, PJ | 2 |
| Carter, R | 1 |
| Holiday, DB | 1 |
| Nwasuruba, C | 1 |
| Stocks, J | 1 |
| Grothues, C | 1 |
| Tiep, B | 1 |
| Masjedi, MR | 1 |
| Jamaati, HR | 1 |
| Dokouhaki, P | 1 |
| Ahmadzadeh, Z | 1 |
| Taheri, SA | 1 |
| Bigdeli, M | 1 |
| Izadi, S | 1 |
| Rostamian, A | 1 |
| Aagin, K | 1 |
| Ghavam, SM | 1 |
| Nishimura, K | 1 |
| Koyama, H | 1 |
| Tsukino, M | 1 |
| Oga, T | 1 |
| Hajiro, T | 1 |
| Mishima, M | 1 |
| Chang, G | 1 |
| Pan, X | 1 |
| Xie, X | 1 |
| Welle, I | 1 |
| Jiménez-Ruiz, C | 1 |
| Sobradillo, V | 1 |
| Gabriel, R | 1 |
| Viejo, JL | 1 |
| Masa, JF | 1 |
| Fernández-Fau, L | 1 |
| Villasante, C | 1 |
| Takizawa, H | 1 |
| Löfdahl, JM | 1 |
| Cederlund, K | 1 |
| Nathell, L | 1 |
| Ong, KC | 1 |
| Cheong, GN | 1 |
| Prabhakaran, L | 1 |
| Earnest, A | 1 |
| Khanna, D | 1 |
| Clements, PJ | 1 |
| Furst, DE | 1 |
| Chon, Y | 1 |
| Elashoff, R | 1 |
| Roth, MD | 1 |
| Sterz, MG | 1 |
| Chung, J | 1 |
| FitzGerald, JD | 1 |
| Seibold, JR | 1 |
| Varga, J | 1 |
| Theodore, A | 1 |
| Wigley, FM | 1 |
| Silver, RM | 1 |
| Steen, VD | 1 |
| Mayes, MD | 1 |
| Connolly, MK | 1 |
| Fessler, BJ | 1 |
| Rothfield, NF | 1 |
| Mubarak, K | 1 |
| Molitor, J | 1 |
| Tashkin, DP | 1 |
| Silkoff, PE | 1 |
| Zhang, L | 1 |
| Dutton, S | 1 |
| Langmack, EL | 1 |
| Vedal, S | 1 |
| Murphy, J | 1 |
| Make, B | 1 |
| Bugnet, AS | 1 |
| Kadaoui, N | 1 |
| Schott, R | 1 |
| Enache, I | 1 |
| Ducoloné, A | 1 |
| Ehrhart, M | 1 |
| Osmanliev, DP | 1 |
| Joyce, H | 1 |
| Watson, RA | 1 |
| Pride, NB | 1 |
| Baldi, S | 2 |
| Pinna, GD | 1 |
| Crotti, P | 1 |
| Montemartini, S | 1 |
| Dacosto, E | 1 |
| Fanfulla, F | 1 |
| Fracchia, C | 2 |
| Bruschi, C | 2 |
| Akuta, T | 1 |
| Akaike, T | 1 |
| Permutt, S | 1 |
| Pearse, DB | 1 |
| Izquierdo, JL | 1 |
| Almonacid, C | 1 |
| Parra, T | 1 |
| Pérez, J | 1 |
| Savani, BN | 1 |
| Montero, A | 1 |
| Srinivasan, R | 1 |
| Singh, A | 1 |
| Shenoy, A | 1 |
| Mielke, S | 1 |
| Rezvani, K | 1 |
| Karimpour, S | 1 |
| Childs, R | 1 |
| Barrett, AJ | 1 |
| Peel, JL | 1 |
| Metzger, KB | 1 |
| Klein, M | 1 |
| Flanders, WD | 1 |
| Mulholland, JA | 1 |
| Tolbert, PE | 1 |
| Lee, IM | 1 |
| Tsai, SS | 1 |
| Chang, CC | 1 |
| Ho, CK | 1 |
| Gosker, HR | 1 |
| Zeegers, MP | 1 |
| Schols, AM | 1 |
| Bathoorn, E | 1 |
| Slebos, DJ | 1 |
| Postma, DS | 1 |
| Koeter, GH | 1 |
| van Oosterhout, AJ | 1 |
| van der Toorn, M | 1 |
| Boezen, HM | 1 |
| Kerstjens, HA | 1 |
| Hanta, I | 1 |
| Kocabas, A | 1 |
| Olgunus, O | 1 |
| Satar, S | 1 |
| Seydaoglu, G | 1 |
| Dore, R | 1 |
| Maestri, R | 1 |
| Brusasco, V | 1 |
| Pellegrino, R | 1 |
| Anderson, GP | 1 |
| Christenhusz, L | 1 |
| de Jongh, F | 1 |
| van der Valk, P | 1 |
| Pieterse, M | 1 |
| Seydel, E | 1 |
| van der Palen, J | 1 |
| Brijker, F | 1 |
| Heijdra, YF | 1 |
| van den Elshout, FJ | 1 |
| Folgering, HT | 1 |
| Kawane, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "(COPD History Assessment In SpaiN): Estudio Sobre la Evolución Multidimensional de la Enfermedad Pulmonar Obstructiva Crónica (EPOC)."[NCT01122758] | 2,400 participants (Anticipated) | Observational | 2009-12-31 | Recruiting | |||
| Genetic Epidemiology of Chronic Obstructive Pulmonary Disease[NCT00608764] | 10,718 participants (Actual) | Observational | 2007-11-30 | Active, not recruiting | |||
| The Boundaries of Mild Chronic Obstructive Pulmonary Disease: Searching Clinical COPD Onset[NCT03026439] | 240 participants (Actual) | Observational | 2014-09-30 | Completed | |||
| The Association of Cigarette Smoking on Exercise Capacity and Skeletal Muscle Function in Taiwan Adult Smokers[NCT04688177] | 52 participants (Actual) | Observational | 2020-12-03 | Completed | |||
| Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics[NCT03002389] | Phase 2 | 95 participants (Anticipated) | Interventional | 2017-11-05 | Recruiting | ||
| Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap[NCT03263130] | 60 participants (Anticipated) | Observational [Patient Registry] | 2017-01-01 | Recruiting | |||
| A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time[NCT00292552] | 2,747 participants (Actual) | Observational | 2005-12-31 | Completed | |||
| Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD[NCT01245933] | 2,741 participants (Actual) | Observational | 2010-11-30 | Active, not recruiting | |||
| Effect of Intermittent Hypoxia on Ischemia-reperfusion Injury in Healthy Individuals[NCT05423470] | 41 participants (Actual) | Interventional | 2019-05-30 | Completed | |||
| Multi-center, Randomized Trial With I.V. Prolastin® to Evaluate Frequency of Exacerbations and Progression of Emphysema by Means of Multi-slice CT Scans in Patients With Congenital Alpha-1-antitrypsin Deficiency.[NCT00263887] | Phase 2 | 77 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| High Intensity Respiratory Muscle Training as a Pre-habilitation in Lung Surgery[NCT04826575] | 150 participants (Anticipated) | Interventional | 2021-03-25 | Recruiting | |||
| Smoking Reduction In Gravid Women With Substance Use Disorders (SIGS): A Randomized Controlled Trial[NCT04132232] | 74 participants (Anticipated) | Interventional | 2021-02-15 | Recruiting | |||
| Clinical & Systems Medicine Investigations of Smoking-related Chronic Obstructive Pulmonary Disease[NCT02627872] | 120 participants (Actual) | Observational | 2007-03-31 | Active, not recruiting | |||
| Cardiovascular Risk and Chronic Obstructive Pulmonary Disease (COPD)[NCT03014609] | 150 participants (Anticipated) | Observational [Patient Registry] | 2017-01-09 | Recruiting | |||
| Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)[NCT00883129] | Phase 2 | 142 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Chronisch Obstruktive Lungenerkrankung Und Pulmonale Hypertonie: Prävalenz Und Lebensqualität[NCT01423071] | 220 participants (Actual) | Observational | 2011-08-31 | Completed | |||
| A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)[NCT01725256] | Phase 2 | 29 participants (Actual) | Interventional | 2012-11-30 | Terminated (stopped due to Terminated early dt to acquisition of Sponsor and change in corporate priorities) | ||
| A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension[NCT01725269] | Phase 2 | 17 participants (Actual) | Interventional | 2013-03-31 | Terminated (stopped due to Terminated early dt acquisition of Sponsor and change in corporate priorities) | ||
| Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans Syndrome[NCT01287078] | Phase 2 | 25 participants (Actual) | Interventional | 2011-01-29 | Completed | ||
| Modification of Chronic Inflammation by Inhaled Carbon Monoxide in Patients With Stable COPD[NCT00122694] | Phase 2 | 20 participants | Interventional | 2005-01-31 | Completed | ||
| A Phase Ib Trial of Inhaled Carbon Monoxide for the Treatment of Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)[NCT04870125] | Phase 1 | 36 participants (Anticipated) | Interventional | 2023-12-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00263887)
Timeframe: 24 or 30 months
| Intervention | g/L (Mean) | ||
|---|---|---|---|
| Baseline | Endpoint | Change from Baseline | |
| Placebo | 45.477 | 41.354 | -4.124 |
| Prolastin (60 mg/kg Body Weight) | 47.980 | 45.085 | -2.895 |
Imaging of the whole lung (WL) is performed using a volumetric high resolution computerized tomography (HRCT) scan, which is then analyzed using a computer algorithm to determine the percentage of overall pixels exhibiting features characteristic for quantitative lung fibrosis (QLF). Higher percentages for QLF-WL therefore represent greater involvement by lung fibrosis. (NCT00883129)
Timeframe: Measured at baseline and Month 24
| Intervention | % of lung exhibiting QLF (Mean) | |
|---|---|---|
| Baseline | Month 24 | |
| Cyclophosphamide Arm | 8.91 | 8.48 |
| Mycophenolate Arm | 8.25 | 7.99 |
The primary outcome is the course over time from baseline to 24 months for the FVC %-predicted. The FVC %-predicted represents the adjusted volume of air (adjusted as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity) that can be forcibly exhaled from the lungs after taking the deepest breath possible. The FVC %-predicted is reduced in patients with interstitial lung disease and is used as a measure of lung involvement and disease severity. (NCT00883129)
Timeframe: Measured at study Baseline and Months 3, 6, 12, 15, 18, 21, and 24
| Intervention | FVC %-pred (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 66.52 | 67.03 | 67.86 | 69.42 | 69.86 | 71.94 | 72.57 | 72.55 | 70.15 |
| Mycophenolate Arm | 66.52 | 66.22 | 68.02 | 68.11 | 68.43 | 69.84 | 70.57 | 70.87 | 69.65 |
The HAQ-DI asks questions related to 8 activity domains (dressing, arising, eating, walking, hygiene, reach, grip, and common daily activities) with the patient's capacity to carry out each activity scored from 0 to 3. Scores across all domains are averaged and a higher score represents greater disability. (NCT00883129)
Timeframe: Measured at study entry and Months 3, 6, 9, 12, 15, 18, 21, and 24
| Intervention | HAQ-DI Total Score (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 0.74 | 0.64 | 0.58 | 0.65 | 0.56 | 0.62 | 0.55 | 0.48 | 0.57 |
| Mycophenolate Arm | 0.71 | 0.83 | 0.75 | 0.66 | 0.64 | 0.58 | 0.55 | 0.65 | 0.62 |
The DLCO is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLCO %-predicted represents the DLCO expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The DLCO %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity. (NCT00883129)
Timeframe: Measured at study entry and Months 3, 6, 12, 15, 18, 21, and 24
| Intervention | DLCO %-pred (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 54.05 | 51.92 | 50.87 | 51.55 | 53.12 | 53.62 | 55.9 | 54.26 | 52.90 |
| Mycophenolate Arm | 53.99 | 53.38 | 54.86 | 54.13 | 55.32 | 57.77 | 56.62 | 55.47 | 55.31 |
Skin thickness is quantified using the modified Rodnan measurement method (mRSS), with a scale that ranges from 0 (no skin involvement) to a maximum of 51. The reported skin score is determined by a clinical assessment of skin thickness, which is performed by a trained reader, and represents the sum of individual assessments that are made in each of 17 body areas. Each area is given a score in the range of 0-3 (0 = normal; 1= mild thickness; 2 = moderate; 3 = severe thickness). A higher score represents more severe skin involvement. (NCT00883129)
Timeframe: Measured at baseline and Months 3, 6, 9, 12, 15, 18, 21, and 24
| Intervention | mRSS score (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 14.04 | 12.85 | 11.95 | 10.61 | 9.47 | 9.80 | 9.87 | 8.50 | 7.87 |
| Mycophenolate Arm | 15.32 | 16.03 | 14.37 | 14.33 | 12.45 | 12.43 | 11.98 | 11.22 | 11.40 |
The number of participants who remained in the study at the listed time points are reported (NCT00883129)
Timeframe: Continuous assessment from randomization to 24 months
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Month 24 | |
| Cyclophosphamide Arm | 73 | 64 | 56 | 51 | 46 | 44 | 42 | 39 | 38 |
| Mycophenolate Arm | 69 | 66 | 58 | 55 | 52 | 52 | 49 | 49 | 49 |
The TLC represents the total volume of air within the lung after taking the deepest breath possible and the TLC %-predicted represents the TLC expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The TLC %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity. (NCT00883129)
Timeframe: Measured at study entry and Months 6, 12, 18, and 24
| Intervention | TLC %-pred (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Month 6 | Month 12 | Month 18 | Month 24 | |
| Cyclophosphamide Arm | 65.49 | 67.39 | 68.25 | 69.63 | 66.97 |
| Mycophenolate Arm | 66.16 | 67.84 | 67.31 | 68.50 | 68.24 |
(NCT00883129)
Timeframe: Measured throughout the 2-year study
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Leukopenia (<2.5x10^3 WBC/microliter) | Neutropenia (<1.0x10^3 neutrophils/microliter) | Anemia (Hgb <10 g/dl) | Thrombocytopenia (<100x10^3 platelets/microliter) | Hematuria (>10 RBC/high power field) | Pneumonia | SAE-Total | SAE-related to treatment | Deaths | |
| Cyclophosphamide Arm | 30 | 7 | 13 | 4 | 2 | 4 | 22 | 7 | 11 |
| Mycophenolate Arm | 4 | 3 | 8 | 0 | 3 | 5 | 27 | 3 | 5 |
Change in breathlessness was assessed using the Transitional Dyspnea Index, which compares current symptoms to those at baseline. Total score ranges from - 9 to + 9. The lower the score, the more deterioration in severity of dyspnea. (NCT00883129)
Timeframe: Measured at Months 6, 12, 18, and 24
| Intervention | Transitional Dyspnea Index Score (Mean) | |||
|---|---|---|---|---|
| Month 6 | Month 12 | Month 18 | Month 24 | |
| Cyclophosphamide Arm | 0.31 | 1.23 | 1.78 | 2.09 |
| Mycophenolate Arm | 0.74 | 1.17 | 0.91 | 1.86 |
Participants with progressive disease at baseline with decline in FEV1 greater than 10% (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 2 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with progressive disease at baseline with stablization of FEV1 (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 2 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with stable disease at baseline with stablization in FEV1 and greater than 25% decline in systemic immunosuppression (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 3 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants who did not respond to treatment with cyclosporine inhalation solution (CIS) (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 7 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 2 |
Participants who responded to treatment with cyclosporine inhalation solution (CIS) (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 9 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with stable disease at baseline with stablization of FEV1 and no change or increase in systemic immunosuppresion (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 4 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 2 |
Participants with stable or progressive disease at baseline with greater than 20% of decline in FEV1 (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 1 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
Participants with stable or progressive disease at baseline with improvement of FEV1 (NCT01287078)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Cyclosporine in HSCT Recipients | 4 |
| Inhaled Cyclosporine in Lung Transplant Recipients | 0 |
16 reviews available for carbon monoxide and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Clinical Indicators for Asthma-COPD Overlap: A Systematic Review and Meta-Analysis.
Topics: Asthma; Carbon Monoxide; Chitinase-3-Like Protein 1; Forced Expiratory Volume; Humans; Immunoglobuli | 2022 |
Recent advances in HIV-associated chronic lung disease clinical research.
Topics: Carbon Monoxide; HIV Infections; HIV-1; Humans; Lung; Lung Diseases; Pulmonary Disease, Chronic Obst | 2021 |
Carbon monoxide in exhaled breath testing and therapeutics.
Topics: Acute Lung Injury; Anesthesia; Animals; Asthma; Biomarkers; Breath Tests; Carbon Monoxide; Cystic Fi | 2013 |
[Compounds in tobacco smoke and pathogenesis of the diseases].
Topics: Carbon Monoxide; DNA Damage; Heart Diseases; Humans; Japan; Nicotine; Pulmonary Disease, Chronic Obs | 2013 |
Diffusing capacity.
Topics: Carbon Monoxide; Diffusion; Evaluation Studies as Topic; Humans; Lung; Lung Diseases, Interstitial; | 2009 |
Risk assessment for pulmonary resection.
Topics: Algorithms; Carbon Monoxide; Cardiovascular Diseases; Exercise Test; Forced Expiratory Volume; Human | 2010 |
Update in environmental and occupational medicine 2010.
Topics: Air Pollution; Asthma; Biomass; Carbon Monoxide; Cardiovascular Diseases; Humans; Lung Diseases; Occ | 2011 |
[Adult respiratory sequelae of premature birth].
Topics: Adolescent; Adult; Bronchial Hyperreactivity; Bronchopulmonary Dysplasia; Carbon Monoxide; Disease P | 2011 |
Heme Oxygenase-1/CO as protective mediators in cigarette smoke- induced lung cell injury and chronic obstructive pulmonary disease.
Topics: Animals; Carbon Monoxide; Heme Oxygenase-1; Humans; Lung Injury; Pulmonary Disease, Chronic Obstruct | 2012 |
Breath biomarkers in diagnosis of pulmonary diseases.
Topics: Asthma; Biomarkers; Breath Tests; Carbon Monoxide; Cystic Fibrosis; Humans; Hydrogen Peroxide; Lung | 2012 |
A challenge to the seven widely believed concepts of COPD.
Topics: Asthma; Basement Membrane; Biopsy; Bronchi; Bronchiectasis; Bronchoscopy; Carbon Monoxide; Diagnosis | 2013 |
Analysis of expired air for oxidation products.
Topics: Asthma; Biomarkers; Breath Tests; Carbon Monoxide; Cystic Fibrosis; Humans; Hydrocarbons; Lipid Pero | 2002 |
[Exhaled nitric oxide (NO), carbon monoxide (CO)].
Topics: Asthma; Biomarkers; Breath Tests; Carbon Monoxide; Humans; Nitric Oxide; Pulmonary Disease, Chronic | 2004 |
Effects of corticosteroids on noninvasive biomarkers of inflammation in asthma and chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Asthma; Biomarkers; Breath Tests; Carbon Monoxi | 2004 |
[Nitric oxide and its related compounds].
Topics: Asthma; Biomarkers; Carbon Monoxide; Chromatography, Gas; Chromatography, High Pressure Liquid; Clin | 2005 |
Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis.
Topics: Biomarkers; Body Mass Index; Carbon Monoxide; Forced Expiratory Volume; Humans; Muscle Fibers, Fast- | 2007 |
13 trials available for carbon monoxide and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Lung function changes in patients with chronic obstructive pulmonary disease (COPD) and asthma exposed to secondhand smoke in outdoor areas.
Topics: Adult; Aged; Air Pollutants; Asthma; Carbon Monoxide; Female; Forced Expiratory Flow Rates; Forced E | 2021 |
Effects of woodsmoke exposure on airway inflammation in rural Guatemalan women.
Topics: Adult; Air Pollutants; Carbon Monoxide; Cohort Studies; Cross-Sectional Studies; Female; Fibronectin | 2014 |
Beyond cigarettes per day. A genome-wide association study of the biomarker carbon monoxide.
Topics: Adult; Biomarkers; Black or African American; Carbon Monoxide; Confidence Intervals; Cytochrome P-45 | 2014 |
Is generalization of exhaled CO assessment in primary care helpful for early diagnosis of COPD?
Topics: Adult; Aged; Area Under Curve; Breath Tests; Carbon Monoxide; Early Diagnosis; Female; Humans; Male; | 2015 |
Clinical Association of Chemokine (C-X-C motif) Ligand 1 (CXCL1) with Interstitial Pneumonia with Autoimmune Features (IPAF).
Topics: Aged; Autoimmune Diseases; Blood Sedimentation; Carbon Monoxide; Chemokine CXCL1; Female; Humans; Id | 2016 |
Intermittent hypoxia increases exercise tolerance in patients at risk for or with mild COPD.
Topics: Adult; Aged; Anaerobic Threshold; Analysis of Variance; Carbon Monoxide; Double-Blind Method; Exerci | 2009 |
Salmeterol improves fluid clearance from alveolar-capillary membrane in COPD patients: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Albuterol; Body Fluids; Bronchodilator Agents; Capillaries; Carbon M | 2012 |
6-minute walk work for assessment of functional capacity in patients with COPD.
Topics: Aged; Carbon Monoxide; Exercise Test; Exercise Tolerance; Female; Forced Expiratory Volume; Humans; | 2003 |
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Topics: Carbon Monoxide; Double-Blind Method; Dyspnea; Female; Health Status; Humans; Lung Diseases; Male; M | 2005 |
Anti-inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Carbon Monoxide; Eosinophils; Female; Fo | 2007 |
Anti-inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Carbon Monoxide; Eosinophils; Female; Fo | 2007 |
Anti-inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Carbon Monoxide; Eosinophils; Female; Fo | 2007 |
Anti-inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Carbon Monoxide; Eosinophils; Female; Fo | 2007 |
Effect of bronchodilatation on single breath pulmonary uptake of carbon monoxide in chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Aged; Albuterol; Bronchodilator Agents; Carbon Monoxide; Emphysema; Fema | 2006 |
Comparison of three carbon monoxide monitors for determination of smoking status in smokers and nonsmokers with and without COPD.
Topics: Adult; Aged; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Predictive | 2007 |
Discontinuation of furosemide decreases PaCO(2) in patients with COPD.
Topics: Aged; Aged, 80 and over; Body Fluids; Carbon Monoxide; Cross-Over Studies; Diuretics; Double-Blind M | 2002 |
110 other studies available for carbon monoxide and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Brief Report: HIV Is Associated With Impaired Pulmonary Diffusing Capacity Independent of Emphysema.
Topics: Carbon Monoxide; Cross-Sectional Studies; Emphysema; HIV Infections; Humans; Lung; Pulmonary Diffusi | 2022 |
The association between transfer coefficient of the lung and the risk of exacerbation in asthma-COPD overlap: an observational cohort study.
Topics: Adult; Aged; Aged, 80 and over; Asthma; Carbon Monoxide; Cohort Studies; Female; Forced Expiratory V | 2022 |
Risk Factors Associated with Impairment in Pulmonary Diffusing Capacity among Patients with Noncystic Fibrosis Bronchiectasis.
Topics: Bronchiectasis; Carbon Monoxide; Fibrosis; Humans; Lung Diseases, Interstitial; Pulmonary Diffusing | 2022 |
An assessment of post-COVID-19 infection pulmonary functions in healthcare professionals.
Topics: Adult; Carbon Monoxide; COVID-19; Delivery of Health Care; Dyspnea; Female; Humans; Lung; Male; Midd | 2022 |
Can FVC/DLCO predict pulmonary hypertension in patients with chronic obstructive pulmonary disease?
Topics: Carbon Monoxide; Humans; Hypertension, Pulmonary; Oxygen; Pulmonary Disease, Chronic Obstructive; Vi | 2022 |
Prevalence of reduced lung diffusing capacity and CT scan findings in smokers without airflow limitation: a population-based study.
Topics: Carbon Monoxide; Humans; Lung; Prevalence; Pulmonary Disease, Chronic Obstructive; Smokers; Tomograp | 2023 |
Association of ambient carbon monoxide exposure with hospitalization risk for respiratory diseases: A time series study in Ganzhou, China.
Topics: Asthma; Carbon Monoxide; China; Female; Hospitalization; Humans; Influenza, Human; Pulmonary Disease | 2023 |
The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity.
Topics: Biomarkers; Carbon Monoxide; Humans; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors | 2023 |
Isolated abnormal diffusing capacity for carbon monoxide (iso↓DLco) is associated with increased respiratory symptom burden in people with HIV infection.
Topics: Asthma; Carbon Monoxide; Cross-Sectional Studies; Forced Expiratory Volume; HIV Infections; Humans; | 2023 |
Ambient carbon monoxide and relative risk of daily hospital outpatient visits for respiratory diseases in Lanzhou, China.
Topics: Air Pollutants; Air Pollution; Asthma; Bronchitis; Carbon Monoxide; Child; China; Female; Hospitals; | 2023 |
Effectiveness of smoking cessation in smokers with COPD and nocturnal oxygen desaturation: Functional analysis.
Topics: Adult; Blood Gas Analysis; Carbon Monoxide; Case-Control Studies; Exhalation; Female; Forced Expirat | 2020 |
The protective effects of thymoquinone on lung damage caused by cigarette smoke.
Topics: Animals; Benzoquinones; Carbon Monoxide; Cytokines; Gene Expression Regulation; Lung Diseases; Male; | 2020 |
Relationship between diffusion capacity and small airway abnormality in COPDGene.
Topics: Aged; Airway Obstruction; Airway Remodeling; Bronchioles; Carbon Monoxide; Cohort Studies; Female; H | 2019 |
Association Between Inflammatory Pathways and Phenotypes of Pulmonary Dysfunction Using Cluster Analysis in Persons Living With HIV and HIV-Uninfected Individuals.
Topics: Adult; Carbon Monoxide; CD4 Lymphocyte Count; Cluster Analysis; Cohort Studies; Female; HIV Infectio | 2020 |
Acute Effects of Air Pollution on Hospital Admissions for Asthma, COPD, and Bronchiectasis in Ahvaz, Iran.
Topics: Age Factors; Air Pollutants; Air Pollution; Asthma; Bronchiectasis; Carbon Monoxide; Hospitalization | 2020 |
Lung function in men with and without HIV.
Topics: Adult; Aged; Carbon Monoxide; Cross-Sectional Studies; Female; Forced Expiratory Volume; HIV Infecti | 2020 |
Predicting the morbidity of chronic obstructive pulmonary disease based on multiple locally weighted linear regression model with K-means clustering.
Topics: Air Pollutants; Carbon Monoxide; China; Humans; Incidence; Linear Models; Models, Statistical; Morbi | 2020 |
Outcomes and predictive factors for successful smoking cessation therapy in COPD patients with nicotine dependence.
Topics: Aged; Carbon Monoxide; Female; Forced Expiratory Volume; Humans; Male; Mental Disorders; Middle Aged | 2020 |
Diffusing Capacity for Carbon Monoxide Is a Reflection of the Pulmonary Microcirculation, but Not Only.
Topics: Carbon Monoxide; Humans; Hypertension, Pulmonary; Microcirculation; Pulmonary Diffusing Capacity; Pu | 2020 |
Two cases of chronic obstructive pulmonary disease with undetectable diffusing capacity for carbon monoxide.
Topics: Aged; Breath Holding; Carbon Monoxide; Humans; Lung; Male; Middle Aged; Pulmonary Diffusing Capacity | 2021 |
Disproportionally Impaired Diffusion Capacity Relative to Airflow Limitation in COPD.
Topics: Aged; Blood Gas Analysis; Carbon Monoxide; Cohort Studies; Cross-Sectional Studies; Female; Forced E | 2020 |
Natural Course of the Diffusing Capacity of the Lungs for Carbon Monoxide in COPD: Importance of Sex.
Topics: Carbon Monoxide; Female; Humans; Male; Phenotype; Pulmonary Diffusing Capacity; Pulmonary Disease, C | 2021 |
Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD.
Topics: Body Mass Index; Canada; Carbon Monoxide; Exercise Tolerance; Female; Humans; Male; Middle Aged; Mor | 2021 |
Prognostic marker for severe acute exacerbation of chronic obstructive pulmonary disease: analysis of diffusing capacity of the lung for carbon monoxide (D
Topics: Aged; Aged, 80 and over; Area Under Curve; Carbon Monoxide; Female; Forced Expiratory Volume; Hospit | 2021 |
Secondary polycythemia in chronic obstructive pulmonary disease: prevalence and risk factors.
Topics: Aged; Aged, 80 and over; Carbon Monoxide; Cigarette Smoking; Cross-Sectional Studies; Female; Humans | 2021 |
Cardiopulmonary exercise testing and second-line pulmonary function tests to detect obstructive pattern in symptomatic smokers with borderline spirometry.
Topics: Aged; Carbon Monoxide; Chest Wall Oscillation; Disease Progression; Exercise Test; Female; Forced Ex | 2017 |
Individualised risk in patients undergoing lung volume reduction surgery: the Glenfield BFG score.
Topics: Aged; Area Under Curve; Body Mass Index; Carbon Monoxide; Decision Making; Female; Forced Expiratory | 2017 |
Assessment of exhaled carbon monoxide in exacerbations of chronic obstructive pulmonary disease.
Topics: Adult; Aged; Biomarkers; Breath Tests; Carbon Monoxide; Case-Control Studies; Disease Progression; E | 2016 |
Hypoxic vascular response and ventilation/perfusion matching in end-stage COPD may depend on p22phox.
Topics: Adult; Animals; Carbon Monoxide; Case-Control Studies; Cytochrome b Group; Female; Humans; Hypertens | 2017 |
Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD.
Topics: Aged; Carbon Monoxide; Exercise Test; Female; Humans; Hypoxia; Lung Diseases, Interstitial; Male; Mi | 2018 |
Endoscopic Lung Volume Reduction in COPD: Improvements in Gas Transfer Capacity Are Associated With Improvements in Ventilation and Perfusion Matching.
Topics: Aged; Carbon Monoxide; Endoscopy; Female; Humans; Male; Middle Aged; Pneumonectomy; Pulmonary Diffus | 2018 |
Characterization of Fine Particulate Matter and Associated Health Burden in Nanjing.
Topics: Adult; Aged; Air Pollutants; Carbon Monoxide; China; Environmental Monitoring; Female; Humans; Lung | 2018 |
Asthma-COPD Overlap Phenotypes and Smoking :Comparative features of asthma in smoking or non-smoking patients with an incomplete reversibility of airway obstruction.
Topics: Aged; Asthma; Carbon Monoxide; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Non-Smoke | 2018 |
Mouse Models of COPD.
Topics: Animals; Biomarkers; Carbon Monoxide; Disease Models, Animal; Electronic Nicotine Delivery Systems; | 2018 |
Hyperpolarized
Topics: alpha 1-Antitrypsin Deficiency; Carbon Monoxide; Diffusion; Diffusion Magnetic Resonance Imaging; Di | 2019 |
Varenicline for long term smoking cessation in patients with COPD.
Topics: Adult; Airway Obstruction; Carbon Monoxide; Cohort Studies; Female; Humans; Longitudinal Studies; Ma | 2018 |
Influence of Mouth Pressure on Measurement of Diffusing Capacity in the Clinical Pulmonary Function Laboratory.
Topics: Adult; Aged; Asthma; Breath Holding; Carbon Monoxide; Dyspnea; Female; Forced Expiratory Volume; Hum | 2019 |
HIV infection is an independent risk factor for decreased 6-minute walk test distance.
Topics: Adult; Carbon Monoxide; Diagnostic Tests, Routine; Female; HIV; HIV Infections; Humans; Lung; Male; | 2019 |
Exhaled carbon monoxide levels in obstructive sleep apnoea.
Topics: Adult; Breath Tests; Carbon Monoxide; Case-Control Studies; Exhalation; Female; Humans; Male; Middle | 2019 |
Diffusing Capacity of Carbon Monoxide in Assessment of COPD.
Topics: Aged; Carbon Monoxide; Cross-Sectional Studies; Female; Forced Expiratory Volume; Humans; Male; Midd | 2019 |
Impaired carbon monoxide diffusing capacity is the strongest predictor of exercise intolerance in COPD.
Topics: Aged; Carbon Monoxide; Exercise Test; Exercise Tolerance; Female; Forced Expiratory Volume; Humans; | 2013 |
Bone stiffness and failure load are related with clinical parameters in men with chronic obstructive pulmonary disease.
Topics: Biomechanical Phenomena; Bone and Bones; Carbon Monoxide; Diffusion; Femur Neck; Humans; Male; Middl | 2013 |
On the role of abnormal DL(CO) in ex-smokers without airflow limitation: symptoms, exercise capacity and hyperpolarised helium-3 MRI.
Topics: Aged; Aged, 80 and over; Antimetabolites; Carbon Monoxide; Diffusion Magnetic Resonance Imaging; Exe | 2013 |
COPD: CardiOPulmonary Disease?
Topics: Carbon Monoxide; Cardiovascular Diseases; Humans; Phenotype; Pulmonary Disease, Chronic Obstructive; | 2013 |
Exhaled carbon monoxide and its associations with smoking, indoor household air pollution and chronic respiratory diseases among 512,000 Chinese adults.
Topics: Adult; Aged; Air Pollution, Indoor; Biomass; Breath Tests; Carbon Monoxide; China; Coal; Cough; Envi | 2013 |
Short-term effectiveness of smoking-cessation treatment on respiratory function and CEA level.
Topics: Benzazepines; Carbon Monoxide; Carboxyhemoglobin; Carcinoembryonic Antigen; Combined Modality Therap | 2013 |
[Single-breath and rebreathing methods for measurement of pulmonary diffusing function: a comparative study].
Topics: Adult; Aged; Carbon Monoxide; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Middle Aged; | 2013 |
Reduction of physical activity in daily life and its determinants in smokers without airflow obstruction.
Topics: Activities of Daily Living; Adult; Anxiety Disorders; Carbon Monoxide; Comorbidity; Cross-Sectional | 2014 |
Minimum clinically important difference in diffusing capacity of the lungs for carbon monoxide among patients with severe and very severe chronic obstructive pulmonary disease.
Topics: Aged; Biomarkers; Carbon Monoxide; Exercise Test; Female; Follow-Up Studies; Forced Expiratory Volum | 2015 |
Skeletal muscle adiposity is associated with physical activity, exercise capacity and fibre shift in COPD.
Topics: Adipose Tissue; Adiposity; Aged; Biomarkers; Carbon Monoxide; Case-Control Studies; Exercise; Exerci | 2014 |
Double tracer gas single-breath washout: reproducibility in healthy subjects and COPD.
Topics: Adult; Aged; Aged, 80 and over; Breath Tests; Carbon Monoxide; Case-Control Studies; Female; Forced | 2014 |
Assessment of lung function in asthma and COPD using hyperpolarized 129Xe chemical shift saturation recovery spectroscopy and dissolved-phase MRI.
Topics: Adolescent; Adult; Asthma; Carbon Monoxide; Computer Simulation; Erythrocytes; Female; Humans; Imagi | 2014 |
Impaired Carbon Monoxide Diffusing Capacity is the strongest lung function predictor of decline in 12 minute-walking distance in COPD; a 5-year follow-up study.
Topics: Aged; Carbon Monoxide; Cross-Sectional Studies; Exercise Test; Exercise Tolerance; Female; Follow-Up | 2015 |
The impact of deployment on COPD in active duty military personnel.
Topics: Adult; Airway Obstruction; alpha 1-Antitrypsin; Ambulatory Care; Carbon Monoxide; Electronic Health | 2014 |
Does ambient CO have protective effect for COPD patient?
Topics: Adolescent; Adult; Aged; Carbon Monoxide; China; Female; Humans; Male; Middle Aged; Pulmonary Diseas | 2015 |
Ambient carbon monoxide and the risk of hospitalization due to chronic obstructive pulmonary disease.
Topics: Air Pollutants; Air Pollution; Carbon Monoxide; Emergency Service, Hospital; Environmental Exposure; | 2014 |
A GIS-based spatial correlation analysis for ambient air pollution and AECOPD hospitalizations in Jinan, China.
Topics: Aged; Aged, 80 and over; Air Pollutants; Air Pollutants, Occupational; Air Pollution; Carbon Monoxid | 2015 |
Relationships between diffusing capacity for carbon monoxide (DLCO), and quantitative computed tomography measurements and visual assessment for chronic obstructive pulmonary disease.
Topics: Aged; Carbon Monoxide; Exhalation; Female; Humans; Male; Middle Aged; Pulmonary Diffusing Capacity; | 2015 |
Indoor air quality, ventilation and respiratory health in elderly residents living in nursing homes in Europe.
Topics: Aged; Aged, 80 and over; Air Pollutants; Air Pollution, Indoor; Carbon Monoxide; Environmental Expos | 2015 |
[Use of COPD-6 Vitalograph in Primary Care as tool for smoking cessation].
Topics: Adult; Carbon Monoxide; Equipment Design; Female; Forced Expiratory Volume; Humans; Male; Middle Age | 2016 |
Determining the diagnostic value of endogenous carbon monoxide in chronic obstructive pulmonary disease exacerbations.
Topics: Aged; Aged, 80 and over; Carbon Monoxide; Carboxyhemoglobin; Case-Control Studies; Emergency Medicin | 2014 |
Emphysema and DLCO predict a clinically important difference for 6MWD decline in COPD.
Topics: Aged; Carbon Monoxide; Exercise Tolerance; Female; Follow-Up Studies; Forced Expiratory Volume; Huma | 2015 |
Diffusion capacity of the lung for carbon monoxide - A potential marker of impaired gas exchange or of systemic deconditioning in chronic obstructive lung disease?
Topics: Aged; Blood Gas Analysis; Blood Glucose; Carbon Dioxide; Carbon Monoxide; Cohort Studies; Female; Fo | 2015 |
Coarse Particulate Air Pollution Associated with Increased Risk of Hospital Admissions for Respiratory Diseases in a Tropical City, Kaohsiung, Taiwan.
Topics: Air Pollution; Asthma; Carbon Monoxide; Cities; Cross-Over Studies; Hospitalization; Humans; Lung Di | 2015 |
Identification of COPD Patients at High Risk for Lung Cancer Mortality Using the COPD-LUCSS-DLCO.
Topics: Age Factors; Aged; Body Mass Index; Carbon Monoxide; Cause of Death; Cohort Studies; Databases, Fact | 2016 |
Risk of COPD with obstruction in active smokers with normal spirometry and reduced diffusion capacity.
Topics: Adult; Antimetabolites; Carbon Monoxide; Female; Forced Expiratory Volume; Humans; Lung; Male; Middl | 2015 |
Lack of Correlation Between Pulmonary and Systemic Inflammation Markers in Patients with Chronic Obstructive Pulmonary Disease: A Simultaneous, Two-Compartmental Analysis.
Topics: Aged; Biomarkers; Body Mass Index; C-Reactive Protein; Carbon Dioxide; Carbon Monoxide; Cohort Studi | 2016 |
The Effect of Different Case Definitions of Current Smoking on the Discovery of Smoking-Related Blood Gene Expression Signatures in Chronic Obstructive Pulmonary Disease.
Topics: Adult; Aged; alpha-L-Fucosidase; Carbon Monoxide; Carrier Proteins; Female; Gene Expression; Humans; | 2016 |
Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): An Ecological Study in the Basque Country, Spain (2000-2011).
Topics: Age Factors; Aged; Aged, 80 and over; Air Pollutants; Carbon Monoxide; Cities; Disease Progression; | 2016 |
Association between Air Pollution and Hemoptysis.
Topics: Adult; Aged; Air Pollution; Bronchial Arteries; Bronchiectasis; Carbon Monoxide; Embolization, Thera | 2016 |
Impact of Air Pollutants on Outpatient Visits for Acute Respiratory Outcomes.
Topics: Acute Disease; Air Pollutants; Air Pollution; Ambulatory Care; Asthma; Bronchitis; Carbon Monoxide; | 2017 |
Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort.
Topics: Aged; Carbon Dioxide; Carbon Monoxide; Cohort Studies; Comorbidity; Diabetes Mellitus; Female; Germa | 2017 |
Effect of postural variations on carbon monoxide diffusing capacity in healthy subjects and patients with chronic obstructive pulmonary disease.
Topics: Adult; Aged; Carbon Monoxide; Case-Control Studies; Female; Humans; Linear Models; Male; Middle Aged | 2009 |
[Pulmonary function tests in chronic obstructive pulmonary disease].
Topics: Blood Gas Analysis; Bronchodilator Agents; Carbon Monoxide; Exercise Test; Forced Expiratory Volume; | 2009 |
Exhaled carbon monoxide as a noninvasive marker of airway neutrophilia after lung transplantation.
Topics: Adult; Airway Obstruction; Bronchiolitis Obliterans; Bronchoalveolar Lavage Fluid; C-Reactive Protei | 2009 |
Urban air pollution and chronic obstructive pulmonary disease-related emergency department visits.
Topics: Adult; Air Pollutants; Air Pollution; Brazil; Carbon Monoxide; Emergency Service, Hospital; Environm | 2009 |
Your racing horses will help you to quit: a lesson for COPD and alpha1-antitrypsin deficiency research.
Topics: alpha 1-Antitrypsin Deficiency; Animals; Carbon Monoxide; Disease Progression; Forced Expiratory Vol | 2009 |
Impact of ambient air pollution on the differential white blood cell count in patients with chronic pulmonary disease.
Topics: Adult; Aged; Air Pollutants; Air Pollution; Animals; C-Reactive Protein; Carbon Monoxide; Environmen | 2010 |
Comparison assessment methods of smoking consequences use in primary care.
Topics: Breath Tests; Carbon Monoxide; Causality; Comorbidity; Emphysema; Environmental Monitoring; Epidemio | 2009 |
Exercise ventilatory inefficiency and mortality in patients with chronic obstructive pulmonary disease undergoing surgery for non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carbon Monoxide; Carcinoma, Non-Small-Cell Lung; Exercise Test; Fema | 2010 |
[About interpretation of exhaled CO in smoking cessation].
Topics: Asthma; Bronchiectasis; Carbon Monoxide; Carboxyhemoglobin; Exhalation; Female; Humans; Male; Pulmon | 2010 |
Quantitative CT measures of emphysema and airway wall thickness are related to D(L)CO.
Topics: Analysis of Variance; Carbon Monoxide; Female; Humans; Linear Models; Lung; Male; Middle Aged; Pulmo | 2011 |
Conditions associated with severe carbon monoxide diffusion coefficient reduction.
Topics: Adult; Aged; Aged, 80 and over; Airway Resistance; Blood Flow Velocity; Carbon Monoxide; Female; Hum | 2011 |
Clinical study of multiple breath biomarkers of asthma and COPD (NO, CO(2), CO and N(2)O) by infrared laser spectroscopy.
Topics: Adolescent; Adult; Asthma; Breath Tests; Carbon Monoxide; Child; Exhalation; Female; Humans; Male; N | 2011 |
Validation of the respiratory toxics exposure score (RTES) for chronic obstructive pulmonary disease screening.
Topics: Adult; Air Pollutants; Biomarkers; Breath Tests; Carbon Monoxide; Cross-Sectional Studies; Environme | 2011 |
Assessing recent smoking status by measuring exhaled carbon monoxide levels.
Topics: Aged; Aging; Carbon Monoxide; Exhalation; Female; Humans; Male; Middle Aged; Models, Biological; Pul | 2011 |
Assessing recent smoking status by measuring exhaled carbon monoxide levels.
Topics: Aged; Aging; Carbon Monoxide; Exhalation; Female; Humans; Male; Middle Aged; Models, Biological; Pul | 2011 |
Assessing recent smoking status by measuring exhaled carbon monoxide levels.
Topics: Aged; Aging; Carbon Monoxide; Exhalation; Female; Humans; Male; Middle Aged; Models, Biological; Pul | 2011 |
Assessing recent smoking status by measuring exhaled carbon monoxide levels.
Topics: Aged; Aging; Carbon Monoxide; Exhalation; Female; Humans; Male; Middle Aged; Models, Biological; Pul | 2011 |
Prevalence and prediction of exercise-induced oxygen desaturation in patients with chronic obstructive pulmonary disease.
Topics: Aged; Carbon Monoxide; Exercise; Exercise Test; Female; Forced Expiratory Volume; Humans; Hypoxia; M | 2012 |
Study on changes of heme oxygenase expression in patients with chronic obstructive pulmonary disease.
Topics: Carbon Monoxide; Forced Expiratory Volume; Heme Oxygenase (Decyclizing); Humans; Lung; Pulmonary Dis | 2002 |
Exercise carbon dioxide retention in chronic obstructive pulmonary disease: a case for ventilation/perfusion mismatch combined with hyperinflation.
Topics: Carbon Monoxide; Exercise; Exercise Test; Exercise Tolerance; Female; Humans; Hypercapnia; Male; Pro | 2002 |
Influence of unequal ventilation on the single breath K(CO) in COPD revealed by comparison with the rebreathing K(CO).
Topics: Adult; Age Factors; Aged; Carbon Monoxide; Humans; Inspiratory Capacity; Middle Aged; Pulmonary Dise | 2002 |
Low levels of nitric oxide and carbon monoxide in alpha 1-antitrypsin deficiency.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Aged; alpha 1-Antitrypsin Deficiency; Bi | 2002 |
The effects of air pollution on acute respiratory conditions.
Topics: Adult; Aged; Air Pollutants; Analysis of Variance; Asthma; Carbon Monoxide; Emergency Service, Hospi | 2003 |
Optimal cutoff level of breath carbon monoxide for assessing smoking status in patients with asthma and COPD.
Topics: Adolescent; Adult; Aged; Asthma; Breath Tests; Carbon Monoxide; Cotinine; Cross-Sectional Studies; F | 2003 |
[Time-series analysis on the relationship between air pollution and daily mortality in Beijing].
Topics: Air Pollutants; Carbon Monoxide; Cause of Death; China; Coronary Disease; Humans; Particle Size; Poi | 2003 |
Pulmonary gas exchange and educational level: a community study.
Topics: Adolescent; Adult; Age Factors; Aged; Air Pollutants, Occupational; Body Height; Carbon Monoxide; Ca | 2004 |
Can cumulative tobacco consumption, FTND score, and carbon monoxide concentration in expired air be predictors of chronic obstructive pulmonary disease?
Topics: Adult; Breath Tests; Carbon Monoxide; Epidemiologic Studies; Female; Humans; Male; Middle Aged; Odds | 2004 |
Bronchoalveolar lavage in COPD: fluid recovery correlates with the degree of emphysema.
Topics: Aged; Analysis of Variance; Bronchoalveolar Lavage Fluid; Bronchoscopy; Carbon Monoxide; Case-Contro | 2005 |
Predictors of success in smoking cessation among hospitalized patients.
Topics: Age of Onset; Asthma; Attitude to Health; Breath Tests; Carbon Monoxide; Cohort Studies; Counseling; | 2005 |
Winter air pollution and disease parameters in advanced chronic obstructive pulmonary disease panels residing in Denver, Colorado.
Topics: Aged; Air Pollution; Altitude; Carbon Monoxide; Circadian Rhythm; Colorado; Environmental Monitoring | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Severe pulmonary hypertension and chronic obstructive pulmonary disease.
Topics: Aged; Airway Obstruction; Blood Pressure; Carbon Monoxide; Case-Control Studies; Dyspnea; Heart; Hum | 2005 |
Evolution of changes in carbon monoxide transfer factor in men with chronic obstructive pulmonary disease.
Topics: Adult; Aged; Anthropometry; Breath Tests; Carbon Monoxide; Disease Progression; Follow-Up Studies; F | 2005 |
Nutritional status and airflow obstruction: two independent contributors to CO diffusing capacity impairment in COPD.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Body Mass Index; Carbon Monoxide; Diffusion; F | 2005 |
Blood carbon monoxide will increase from a decline in pulmonary function alone.
Topics: Carbon Monoxide; Carboxyhemoglobin; Humans; Lung; Pulmonary Disease, Chronic Obstructive; Reactive O | 2005 |
[Systemic and lung inflammation in 2 phenotypes of chronic obstructive pulmonary disease].
Topics: Carbon Monoxide; Diffusion; Dinoprost; Emphysema; Humans; Hydrogen-Ion Concentration; Interleukin-8; | 2006 |
Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation.
Topics: Adolescent; Adult; Carbon Monoxide; Child; Chronic Disease; Comorbidity; Disease Progression; Female | 2006 |
Ambient air pollution and cardiovascular emergency department visits in potentially sensitive groups.
Topics: Air Pollution; Carbon Monoxide; Cardiovascular Diseases; Comorbidity; Cross-Over Studies; Diabetes C | 2007 |
Air pollution and hospital admissions for chronic obstructive pulmonary disease in a tropical city: Kaohsiung, Taiwan.
Topics: Air Pollution; Carbon Monoxide; Cross-Over Studies; Hospitalization; Humans; Nitrogen Dioxide; Odds | 2007 |
Does the expired-air carbon monoxide level reflect the severity of inflammation in COPD?
Topics: Aged; Breath Tests; Carbon Monoxide; Female; Forced Expiratory Volume; Humans; Inflammation; Male; M | 2007 |
The COPD CO-factor.
Topics: Carbon Monoxide; Heme Oxygenase (Decyclizing); Humans; Oxidative Stress; Pulmonary Disease, Chronic | 2007 |
Exhaled carbon monoxide in COPD.
Topics: Breath Tests; Carbon Monoxide; Carboxyhemoglobin; Humans; Pulmonary Disease, Chronic Obstructive; Sm | 2002 |